Published • loading... • Updated
FDA Official Who Scrutinized COVID Shots and Antidepressants Is Out in Latest Shake
Dr. Mike Davis will lead the drug center after Tracy Beth Hoeg’s exit, as the FDA continues a leadership turnover that has already included two other departures.
- On Friday, the FDA announced that Tracy Beth Hoeg is stepping down as acting drug center director, with Mike Davis, the center's deputy director, replacing her.
- Hoeg's departure marks the latest transition in an ongoing shake-up at the FDA, following FDA Commissioner Marty Makary's resignation earlier this week and Vinay Prasad's departure last month.
- During her tenure, Hoeg conducted an "initial analysis" linking COVID-19 vaccines to 10 reported deaths in children without providing evidence, while remaining closely aligned with Makary and Health Secretary Robert.
- The agency also announced Friday that Karim Mikhail, a longtime pharmaceutical executive hired by Makary last spring, will assume the role of acting vaccines center director.
- Hoeg's exit underscores a revolving door of leadership changes at the agency, where recent appointees including her lacked the decades of career scientific experience typically required for center director positions.
Insights by Ground AI
23 Articles
23 Articles
A Food and Drug Administration (FDA) official involved in screening the safety of antidepressants, COVID-19 vaccines and other extended-use therapies was removed from her position as head of the agency's drug program.
Coverage Details
Total News Sources23
Leaning Left11Leaning Right1Center8Last UpdatedBias Distribution55% Left
Bias Distribution
- 55% of the sources lean Left
55% Left
L 55%
C 40%
Factuality
To view factuality data please Upgrade to Premium
